Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDR Brachytherapy as Monotherapy for Prostate Cancer
NCT02346253Completed
- Sponsor
- Stanford University
- Start
- Jan 2015
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Open-label, single-arm trial in prostate cancer (PCa), sponsored by Stanford University. Primary endpoint: Proportion of patients with acute grade 2 or greater acute genitourinary (GU) toxicity, scored according to CTCAE v3.0 at 6 months. Started Jan 2015; status: completed.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02346253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346253.